Galapagos NV has successfully identified a second preclinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK) and reached a milestone on another compound, triggering payments to Galapagos totaling $7.3 million. This small molecule candidate meets all of the chemical and biological criteria set by GSK and is now ready for scale up chemistry and safety studies. Phase I trials are expected to begin in 2010. “Six months after announcing our first pre-clinical candi...